Press monitoring
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
9.11.2015 | Press monitoring
TEL-AVIV, Israel, Nov. 9, 2015 (GLOBE NEWSWIRE) - RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced,...
Sanofi Pasteur Reveals its Research on a \"Universal\" Influenza Vaccine
9.11.2015 | Press monitoring
Lyon, France - November 9, 2015 - Sanofi Pasteur , the vaccines division of Sanofi , presented today at the World Vaccine Congress being held in Madrid, Spain, on developing broadly cross-reactive antigens against seasonal and pandemic influenza. The World Vaccine Congress in Europe is in its 16 th year and is a major destination for vaccine...
Medtronic Launches VenaSeal Closure System in the United States; Treats First Patient for Clinically Symptomatic Venous Reflux
9.11.2015 | Press monitoring
DUBLIN - November 9, 2015 - Medtronic plc (NYSE: MDT) today announced U.S. availability of the VenaSeal(TM) closure system, the first and only non-tumescent, non-thermal, non-sclerosant procedure approved for the treatment of symptomatic venous reflux in the U.S. The VenaSeal closure system was approved through the FDA's Pre-Market Approval (PMA)...
Scientists produce beneficial natural compounds in tomato
9.11.2015 | Press monitoring
Scientists at the John Innes Centre have found a way to produce industrial quantities of useful natural compounds efficiently, by growing them in tomatoes. The compounds are phenylpropanoids like Resveratrol, the compound found in wine which has been reported to extend lifespan in animal studies, and Genistein, the compound found in soybean which...
Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
6.11.2015 | Press monitoring
Paris and The Woodlands, TX - November 6, 2015 - Sanofi and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and...
CROSSJECT secures €6.7 million in funding for the development of three new drugs
6.11.2015 | Press monitoring
Chenôve, France - November 6, 2015, 8.30am - CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), specialty pharma company specialized in self-injectable drugs for use in emergency situations, announces that it has been awarded by Bpifrance a refundable grant of €6.7 million, over three years, as part of the Industrial Projects of the Future (Projets...
Researchers want to turn acid-loving microbes into safe drug-carriers
6.11.2015 | Press monitoring
Usually the microbe S. islandicus is found in hot and acidic volcanic springs, but now the microbe has also found its way to the labs of University of Southern Denmark. Here researchers have for the first time showed that the exotic microbe is capable of delivering drugs to the human body. The microbe S. islandicus has a strange and unique talent...
Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
5.11.2015 | Press monitoring
Paris, France and Seoul, Korea - Nov. 5, 2015 - Sanofi and Hanmi Pharmaceutical Co., Ltd. announced today a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
5.11.2015 | Press monitoring
PHILADELPHIA and OXFORD, UK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents updated data on its lead clinical program, an affinity enhanced T-cell receptor therapy targeting the NY-ESO-1 cancer antigen in synovial sarcoma, at the...
Singulex Receives European Patent Expanding Use of Biomarkers Troponin I and T to Detect Cardiac Health Status With High-Sensitivity Methods
5.11.2015 | Press monitoring
ALAMEDA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) - Singulex, Inc. , the developer of Single Molecule Counting technology for use in both medical practice diagnostics and scientific research, has received from the European Patent Office (EPO) a key patent (EP2002260) for use of the biomarkers troponin I and T to detect cardiac damage in humans using...
